Factor VIII Inhibitor - 2018 Pipeline Insights with Detailed Analysis of 2 Active Products: Caplacizumab (Ablynx) and SHP655 (Shire) - ResearchAndMarkets.com

DUBLIN--()--The "Factor VIII Inhibitor - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report outlays comprehensive insights of present scenario and growth prospects across Factor VIII Inhibitor.

A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of two active products, i.e., Caplacizumab of Ablynx and SHP655 of Shire.

Products Covered by Phase

  • Filed & Phase III
  • Inactive (Dormant and Discontinued)

Overview of Pipeline Development Activities for Factor VIII Inhibitor

  • Provides an overview of therapeutic pipeline activity for Factor VIII Inhibitor across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of Factor VIII Inhibitor therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across Factor VIII Inhibitor

Companies Featured

  • Ablynx
  • Shire
  • ThromboGenics
  • Ajinomoto
  • BioVascular
  • Archemix Corporation
  • Glenmark
  • Sanofi

Key Topics Covered

  1. Overview
  2. Factor VIII
  3. Structure
  4. A-Domain
  5. B-Domain
  6. C-Domain
  7. Mechanism of Action
  8. Factor VIII Mutation
  9. Indications related to Factor VIII
  10. Thrombotic thrombocytopenic purpura (TTP)
  11. Thrombosis
  12. Acute coronary syndrome
  13. Factor VIII/ von Willebrand Factor Complex
  14. Pipeline Therapeutics
  15. Late Stage Products (Filed & Phase III)
  16. Comparative Analysis
  17. Caplacizumab: Ablynx
  18. Product Description
  19. Research and Development
  20. Product Development Activities
  21. Inactive Products
  22. Comparative Analysis
  23. Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/hkd7dg/factor_viii?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Hematological Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Hematological Drugs